Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Active, not recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:04 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10492
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Active, not recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 37–48 of 10,492 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449936
View directory record Official record
Conditions
Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
Interventions
EYP-1901, Aflibercept (2.0 mg)
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
53
States / cities
Bakersfield, California • Encino, California • Glendale, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 2:04 PM EST
Active, not recruiting Not applicable Interventional

Memory Gel and Shape Combined Cohort

NCT02919592
View directory record Official record
Conditions
Primary Breast Augmentation, Primary Breast Reconstruction, Revision Breast Augmentation, Revision Breast Reconstruction
Interventions
MemoryShape® Breast Implants, MemoryGel® Breast Implants, Other Aesthetic Surgery
Device · Procedure
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
3,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
78
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 2:04 PM EST
Active, not recruiting No phase listed Observational

RETHINK REFLUX Registry

NCT04253392
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
LINX Reflux Management System
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
21 Years to 99 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
21
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 2:04 PM EST
Active, not recruiting Phase 1 Interventional

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

NCT04652960
View directory record Official record
Conditions
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Duvelisib, Nivolumab, Positron Emission Tomography, Punch Biopsy
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Aurora, Colorado • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 2:04 PM EST
Active, not recruiting Phase 3 Interventional

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Talquetamab, Daratumumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • Little Rock, Arkansas • Norwalk, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 2:04 PM EST
Active, not recruiting Phase 1 Interventional

ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer

NCT04662580
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
ARX517, Apalutamide, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 2:04 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

NCT06095102
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
28
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Encinitas, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 2:04 PM EST
Active, not recruiting Phase 3 Interventional

A Long-term Extension Study of Ustekinumab in Pediatric Participants

NCT05092269
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Interventions
Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 2:04 PM EST
Active, not recruiting Phase 2 Interventional

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

NCT06444880
View directory record Official record
Conditions
SMARCB1-Deficient Malignancies, Epithelioid Sarcoma, Renal Medullary Carcinoma
Interventions
Ubamatamab, Cemiplimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 2:04 PM EST
Active, not recruiting Phase 2 Interventional

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

NCT07230860
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
JNJ-95597528, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Fountain Valley, California • Los Angeles, California • Santa Ana, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 2:04 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT03462719
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Louisville, Kentucky • Hackensack, New Jersey • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 2:04 PM EST
Active, not recruiting Phase 2 Interventional Results available

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03113487
View directory record Official record
Conditions
Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
Interventions
Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 2:04 PM EST